UPPSALA, Sweden, Jan. 9, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the proprietary drug ...
- Findings to be Presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology Overproduction of androstenedione, a key adrenal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results